Trial Profile
Circulating FGF21 Levels and Efficacy of Exemestane, Everolimus and Metformin in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer and BMI ≥ 25
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary) ; Metformin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 22 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 06 Jul 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2019.
- 06 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.